BERKELEY, CA – Nov. 29, 2022
Actym Therapeutics announces that Dr. Akshata Udyavar, Senior Director of Immunology and Translational Sciences, has been invited to speak at the Oncolytic Viruses/ Non-Viral Gene Therapy Delivery Conference, to be held virtually on Dec 1, 2022. The title of Dr. Udyavar’s presentation is “ACTM-838: A Novel Immunotherapy that Enriches in Solid Tumors after IV Dosing and Reverses the Immunosuppressive TME to Promote Durable Anti-Tumor Immunity”. The presentation will begin at 10:35 AM EST. Dr. Udyavar will participate in a question-and-answer session directly after the presentation.
For more information, please see:
About Actym Therapeutics
Actym Therapeutics is a privately held, Berkeley-based biotechnology company focused on the discovery and development of transformational immunotherapies to treat cancer. The company has developed an avirulent, de-immunized, programmable, live immunotherapeutic modality called STACT (S. Typhimurium-Attenuated Cancer Therapy).
After IV dosing, STACT naturally and selectively expands in the extracellular milieu of the TME, an environment well-known to be hospitable for bacterial growth. Once there, it is naturally internalized by phagocytic, tumor-resident immune cells, facilitating combinatorial payload delivery to these cells. This approach enables the tumor-specific delivery of payloads (and combos) too toxic to be dosed systemically via conventional modalities, in a single therapeutic composition. Actym’s lead candidate, ACTM-838 leverages these capabilities and is being tested as a single agent and in combination with anti-PD1 therapy across multiple solid tumor types. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.
Gwen Gordon Public Relations